Bio-Rad adds SARS-CoV-2 to RP positive run control
Oct. 11, 2021—Bio-Rad announced its Exact Diagnostics RP Positive Run Control for syndromic respiratory panels is now available with inactivated whole virus for SARS-CoV-2.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Sysmex introduces hematology analyzer for malaria detection
Oct. 1, 2021—Sysmex America has introduced its XN-30 research use only automated hematology analyzer for malaria detection. The analyzer differentiates P. falciparum from non-falciparum species and determines the life-cycle staging of the parasites detected.
Bio-Rad launches IgA, IgM SARS-CoV-2 Bio-Plex Pro panels
Sept. 30, 2021—Bio-Rad Laboratories launched its Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens.
Seegene unveils molecular testing system
Sept. 29, 2021—Seegene unveiled its first fully automated PCR testing system, Starlet-AIOS, at the 2021 AACC annual meeting, Sept. 26–30, in Atlanta.
Paige Prostate software receives FDA approval
Sept. 23, 2021—The FDA authorized marketing of Paige’s software Paige Prostate, a prostate cancer detection solution that identifies foci suspicious for cancer and provides this information to a pathologist.
Simplexa COVID-19, flu A/B assay assay gets CE mark
Sept. 21, 2021—DiaSorin Molecular announced that it has CE marked its Simplexa COVID-19 and Flu A/B Direct kit.
FDA clears test that differentiates bacterial, viral infections
Sept. 20, 2021—MeMed announced FDA 510(k) clearance for use of the company’s MeMed BV test on the MeMed Key platform to help health care providers distinguish between bacterial and viral infections.
PreciseMDX introduces digital health platform
Aug. 31, 2021—PreciseMDX introduced a cloud-based solution that enables labs to set up scalable, personalized, digital experiences.
Visby gets FDA clearance, CLIA waiver for POC STI test
Aug. 30, 2021—Visby Medical announced it has received FDA 510(k) clearance and was granted a CLIA waiver to market its single-use PCR diagnostic test for the multiplexed detection of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis using a self-collected vaginal swab.
FDA approves Oncomine Dx Target test as a CDx for Tibsovo
Aug. 27, 2021—The FDA has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target test as a companion diagnostic to identify patients with isocitrate dehydrogenase-1 mutated cholangiocarcinoma who may be candidates for Tibsovo (ivosidenib tablets).